Decentralised Clinical Trials: From Adoption to Execution Risk

25 March 2026.

Decentralised clinical trials are no longer defined by adoption, but by how well they can be executed at scale.

What began as a model to improve access and recruitment is now exposing a different set of challenges. As trials become more data-intensive and geographically distributed, consistency of delivery is emerging as the real constraint.

This article examines how decentralisation is shifting from a growth story to an execution test, and what that means for sponsors, CROs and technology providers.

According to Visiongain’s latest analysis, the decentralised clinical trials market is expected to grow from US$11.3 billion in 2026 to US$33.5 billion by 2036, at a CAGR of 11.5%, reflecting both strong demand and increasing operational complexity as the model scales.

Visiongain Top Takeaways

Execution is replacing adoption as the key differentiator in DCT delivery
Hybrid models are becoming the default across most therapeutic areas
Data management, not recruitment, is emerging as the primary constraint
The vendor landscape is shifting towards more integrated delivery models
Operational gaps are widening between early leaders and the rest of the market

Decentralised Clinical Trials Are Becoming Harder to Get Right

Decentralised clinical trials have moved quickly from concept to common practice. Most large sponsors now use remote monitoring, digital tools or hybrid designs as part of standard delivery.

What has changed is not adoption, but the difficulty of making these models work reliably.

Early gains were relatively straightforward. Reducing patient travel and enabling remote visits improved recruitment and retention without fundamentally changing how trials were run.

The challenge now is different. As protocols become more complex and trials span multiple regions, maintaining consistency becomes harder, and small inefficiencies begin to compound.

The Constraint Has Shifted From Access to Control

Access was long a defining limitation in clinical trials. Decentralised approaches have made participation more flexible and, in many cases, more inclusive.

But easing access has exposed a different problem. The constraint is no longer getting patients into trials, but maintaining control once they are enrolled.

Sponsors are now managing continuous data flows, remote interactions and distributed infrastructure. This introduces variability across data capture, monitoring and protocol adherence, making consistency the defining challenge.

Complexity Is Increasing Faster Than Operational Maturity

Modern trials generate far more data than traditional studies. Wearables, remote monitoring and patient-reported inputs are creating continuous, multi-source data streams.

This improves visibility but also introduces new pressure points.

Data must be integrated, validated in near real time and aligned with evolving regulatory standards. Where systems are fragmented, decision-making slows and rework increases.

The gap between organisations is becoming clearer; some can manage this complexity effectively, while others are still adapting.

Hybrid Models Are Emerging as the Practical Standard

Fully virtual trials still attract attention, but remain limited in practice.

Hybrid models are where most of the market is settling. They allow sponsors to retain site-based oversight where needed, while using decentralised elements to extend reach and reduce patient burden.

They are not simpler, but they are more workable across different trial types and regions.

Large pharmaceutical companies such as Pfizer, Novartis and Johnson & Johnson are already applying these models across multiple programmes.

The Vendor Landscape Is Consolidating Around Integration

The market is moving beyond specialist point solutions towards more integrated models.

CROs are expanding decentralised capabilities, while technology providers are building broader platforms through partnerships and acquisitions. Companies such as IQVIA, ICON and Labcorp Drug Development are moving further into end-to-end delivery, while platforms like Medable, Veeva Systems and Medidata continue to expand their scope.

For sponsors, the focus is shifting from selecting tools to ensuring systems work together effectively.

Execution Gaps Are Becoming Competitive Gaps

Not all organisations are progressing at the same pace. Some have built integrated capabilities across technology, operations and regulatory alignment. Others remain more fragmented.

At scale, this difference becomes material. Execution gaps now affect timelines, cost control and data reliability, turning operational capability into a source of competitive advantage.

Looking ahead

The decentralised clinical trials market will continue to expand, but growth alone will not define success.

The next phase will be shaped by how well organisations manage complexity in practice. That includes handling data, coordinating across partners and maintaining consistency across regions.

Those who can do this effectively will be better positioned to scale; those who cannot are likely to face increasing friction as trial complexity rises.

Visiongain Insight: The competitive divide in decentralised trials is shifting from innovation to execution. The organisations that will lead the next phase of the market are those that can deliver repeatable, integrated and scalable trial models, not just adopt new technologies.

From Visiongain

Visiongain’s latest Decentralised Clinical Trials Market Report 2026–2036 examines how this shift is reshaping trial design, delivery models and competitive positioning.

Request sample pages to see where execution capability is becoming a decisive advantage and how leading organisations are positioning to scale.

Latest Reports

Detailed market forecasts, competitive analysis, and sector reports help you make clear, future-proof strategic choices across R&D, manufacturing, supply chain, and commercial execution.

Press & Media Enquiries

For commentary, data requests or interview enquiries, please contact: press@visiongain.com